tradingkey.logo

ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Followed By THP Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In High-Risk HER2-Positive Early-Stage Breast Cancer In DESTINY-Breast11

ReutersMay 7, 2025 11:09 AM

- AstraZeneca PLC AZN.L:

  • ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) FOLLOWED BY THP BEFORE SURGERY SHOWED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PATHOLOGIC COMPLETE RESPONSE IN HIGH-RISK HER2-POSITIVE EARLY-STAGE BREAST CANCER IN DESTINY-BREAST11

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI